The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes

Cardiovascular Drugs and Therapy
J D Fitzgerald


Despite the fact that beta blockers were introduced into clinical practice 25 years ago, new beta blockers with differing kinetic and dynamic profiles continue to be developed and marketed. This overview assesses some of the more extensively studied agents from the point of view of proof of utility and the validity of claims for therapeutic advances. The clinical data suggests that despite the expectations of improvements based on kinetic and dynamic consideration, none of the newer agents have been shown unequivocally, either in terms of efficiency or tolerability, to be an advance over the reference agents, the beta 1 antagonists atenolol and metoprolol. This may be either because such improvements will not occur or because of shortcomings in the design and duration of comparative studies. There are trends to suggest that celiprolol has lesser effects on bronchial function and that it has a lesser impact on lipoprotein profiles. Approaches are suggested that might enable clinicians to appraise for themselves the validity of claims for the improved efficiency of new beta blockers.


Jun 19, 1976·British Medical Journal·A J MarshallD W Barritt
Aug 1, 1977·British Journal of Clinical Pharmacology·D G McDevitt
Nov 1, 1978·Clinical and Experimental Pharmacology & Physiology·J D Fitzgerald, S R O'Donnell
Jan 11, 1990·European Heart Journal·J KjekshusJ Ross
Mar 11, 1990·The American Journal of Cardiology·A HjalmarsonJ Ross
Jan 1, 1990·European Journal of Clinical Pharmacology·L WidmannM Machwirth
Aug 1, 1990·British Journal of Clinical Pharmacology·D G Waller
Sep 1, 1990·British Journal of Clinical Pharmacology·C J Bulpitt, A E Fletcher
Jan 1, 1986·Journal of Cardiovascular Pharmacology·B N Prichard, B Tomlinson
Jan 1, 1986·Journal of Cardiovascular Pharmacology·S H TaylorB Silke
Jan 1, 1986·Journal of Cardiovascular Pharmacology·A E Tattersfield
Jan 1, 1986·Journal of Cardiovascular Pharmacology·W Hoffmann, H Hoffmann
Jan 1, 1987·Journal of Cardiovascular Pharmacology·E SchnurrM Glocke
Jan 1, 1989·Clinical and Experimental Hypertension. Part A, Theory and Practice·S MacMahon
Sep 1, 1985·Japanese Journal of Pharmacology·Y ShirasawaM Nakamura
Sep 1, 1986·British Journal of Pharmacology·A J Kaumann, B M Lobnig
Oct 1, 1986·Scottish Medical Journal·R J NorthcoteD Ballantyne
May 15, 1987·The American Journal of Cardiology·B N Prichard
Feb 10, 1988·The American Journal of Cardiology·R J Norris
Dec 1, 1987·Journal of Clinical Pharmacy and Therapeutics·J V Okopski
Oct 1, 1988·Revista de medicina de la Universidad de Navarra·I GalendeJ Honorato
Feb 10, 1988·The American Journal of Cardiology·P Dorow
Aug 1, 1987·Cardiovascular Drugs and Therapy·K R Courtney
Oct 26, 1988·European Journal of Pharmacology·A Van de WaterP A Janssen
Jul 1, 1988·American Journal of Hypertension·M H RazaviH G Preuss
Jun 26, 1986·The New England Journal of Medicine·S H CroogG H Williams
Jan 1, 1986·European Journal of Clinical Pharmacology·R E RuffinJ H Alpers
Feb 1, 1967·Electroencephalography and Clinical Neurophysiology·J A Hobson
Jan 1, 1974·Naunyn-Schmiedeberg's Archives of Pharmacology·K H RahnG Planz
Jan 1, 1968·British Journal of Pharmacology and Chemotherapy·D Dunlop, R G Shanks
Mar 23, 1972·The New England Journal of Medicine·R ZacestJ Koch-Weser
May 1, 1969·Clinical Pharmacology and Therapeutics·J D Fitzgerald
Sep 1, 1966·The American Journal of Cardiology·E M Williams
Apr 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·A J Kaumann, J R Blinks
Jan 1, 1982·British Journal of Clinical Pharmacology·W J Louis, J J McNeil
Jan 1, 1983·Acta Medica Scandinavica·E FelekeL Rydén
Nov 10, 1983·The American Journal of Cardiology·S H Taylor
Jan 1, 1984·European Journal of Clinical Pharmacology·M M Kubik, J H Coote
Jan 1, 1983·Journal of Cardiovascular Pharmacology·P van Brummelen
May 1, 1983·Journal of Cardiovascular Pharmacology·A J BilskiJ L Wale
May 1, 1984·The American Journal of Emergency Medicine·H N Hart
Apr 1, 1980·Australian and New Zealand Journal of Medicine·S N HunyorH Larkin
Aug 1, 1982·American Heart Journal·P Krupp, A Fanchamps
Jun 1, 1984·Biological Trace Element Research·D J HorvathJ L Frost


Sep 19, 2008·Biomedical Chromatography : BMC·B BuszewskiTomasz Kowalkowski
Feb 18, 2011·British Journal of Pharmacology·J Daniel HothersallJames R Baker
Jun 19, 2001·The Cochrane Database of Systematic Reviews·S SalpeterE Salpeter
Mar 11, 2016·The Cochrane Database of Systematic Reviews·Gavin W K WongJames M Wright
Oct 20, 2005·The Cochrane Database of Systematic Reviews·S SalpeterE Salpeter
Jan 10, 2003·The Cochrane Database of Systematic Reviews·S SalpeterE Salpeter

Related Concepts

Adrenergic beta-Antagonists
Investigational New Drugs

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.